Skip to content Skip to menu

Patients to benefit from new PBS listings

Tuesday, 21 February 2012

Media Release

The listing of nine prescription medicines on the Pharmaceutical Benefits Scheme announced by the Federal Minister for Health Tanya Plibersek will provide patients with affordable access to cost-effective treatments, Medicines Australia chief executive Brendan Shaw said today.

Dr Shaw said the new listings would provide additional options for patients suffering from conditions including juvenile arthritis, chronic myeloid leukaemia and myocardial infarction.

“The PBS listings will be welcomed by patients and I am encouraged by the Government’s commitment to making these medicines available,” Dr Shaw said.

“It is critical for patients that the Government maintain a consistent approach to the listing of medicines recommended by the Pharmaceutical Benefits Advisory Committee.

“This task has been made easier by the Memorandum of Understanding between Medicines Australia and the Commonwealth that will deliver taxpayers $1.9 billion in PBS savings.

“If this is a return to business as usual by the Government it is very welcome. However, the Government does not yet have a clean slate with listing new medicines on the PBS.

“Having gone through the TGA process, the PBAC process, the PBPA process and the Cabinet process, the anti-stroke medicine Pradaxa is now being made to go through another unanticipated hurdle: the anti-coagulant review process.

“I urge the Government to conduct this review as quickly as possible given Pradaxa was first considered by Cabinet in September 2011.”

The nine new PBS listings are:

  • Ticagrelor (Brilinta®), for acute coronary syndrome, manufactured by Astra Zeneca;
  • Cefuroxime axetil (Zinnat®), antibiotic, GlaxoSmithKline;
  • Dasatinib ((Sprycel®), chronic myeloid leukaemia, Bristol-Myers Squibb;
  • Nilotinib (Tasigna®), chronic myeloid leukaemia, Novartis;
  • Dalteparin sodium (Fragmin®), anti-coagulant, Pfizer;
  • Epoprostenol sodium (Flolan®), pulmonary arterial hypertension, GlaxoSmithKline;
  • Morphine sulphate (Kapanol®), pain management, GlaxoSmithKline;
  • Tocilizumab (Actemra®), juvenile arthritis, Roche Products;
  • Abatacept (Orencia®), rheumatoid arthritis, Bristol-Myers Squibb.

-ENDS-

Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293
Email:
Jamie.Nicholson@medicinesaustralia.com.au

Information

As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at medicinesaustralia.com.au/covid-19/

Top